74 related articles for article (PubMed ID: 24518095)
1. Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer.
Ren S; Hirsch FR; Varella-Garcia M; Aisner DL; Boyle T; Zhou C; Camidge DR
J Thorac Oncol; 2014 Mar; 9(3):e21-3. PubMed ID: 24518095
[No Abstract] [Full Text] [Related]
2. ALK-gene rearrangement: a comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma.
Ilie M; Long E; Butori C; Hofman V; Coelle C; Mauro V; Zahaf K; Marquette CH; Mouroux J; Paterlini-Bréchot P; Hofman P
Ann Oncol; 2012 Nov; 23(11):2907-2913. PubMed ID: 22735679
[TBL] [Abstract][Full Text] [Related]
3. ALK in lung cancer: past, present, and future.
Shaw AT; Engelman JA
J Clin Oncol; 2013 Mar; 31(8):1105-11. PubMed ID: 23401436
[TBL] [Abstract][Full Text] [Related]
4. Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation.
Jenkins RW; Oxnard GR; Elkin S; Sullivan EK; Carter JL; Barbie DA
Clin Lung Cancer; 2015 Sep; 16(5):e101-4. PubMed ID: 25769807
[No Abstract] [Full Text] [Related]
5. Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Shaw AT; Ou SH; Bang YJ; Camidge DR; Solomon BJ; Salgia R; Riely GJ; Varella-Garcia M; Shapiro GI; Costa DB; Doebele RC; Le LP; Zheng Z; Tan W; Stephenson P; Shreeve SM; Tye LM; Christensen JG; Wilner KD; Clark JW; Iafrate AJ
N Engl J Med; 2014 Nov; 371(21):1963-71. PubMed ID: 25264305
[TBL] [Abstract][Full Text] [Related]
6. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.
Katayama R; Kobayashi Y; Friboulet L; Lockerman EL; Koike S; Shaw AT; Engelman JA; Fujita N
Clin Cancer Res; 2015 Jan; 21(1):166-74. PubMed ID: 25351743
[TBL] [Abstract][Full Text] [Related]
7. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
Friboulet L; Li N; Katayama R; Lee CC; Gainor JF; Crystal AS; Michellys PY; Awad MM; Yanagitani N; Kim S; Pferdekamper AC; Li J; Kasibhatla S; Sun F; Sun X; Hua S; McNamara P; Mahmood S; Lockerman EL; Fujita N; Nishio M; Harris JL; Shaw AT; Engelman JA
Cancer Discov; 2014 Jun; 4(6):662-673. PubMed ID: 24675041
[TBL] [Abstract][Full Text] [Related]
8. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer.
Zinner RG; Obasaju CK; Spigel DR; Weaver RW; Beck JT; Waterhouse DM; Modiano MR; Hrinczenko B; Nikolinakos PG; Liu J; Koustenis AG; Winfree KB; Melemed SA; Guba SC; Ortuzar WI; Desaiah D; Treat JA; Govindan R; Ross HJ
J Thorac Oncol; 2015 Jan; 10(1):134-42. PubMed ID: 25371077
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic features of patients with non-small cell lung cancer harboring the EML4-ALK fusion gene: a meta-analysis.
Wang Y; Wang S; Xu S; Qu J; Liu B
PLoS One; 2014; 9(10):e110617. PubMed ID: 25360721
[TBL] [Abstract][Full Text] [Related]
10. ALK rearrangement testing by FISH analysis in non-small-cell lung cancer patients: results of the first italian external quality assurance scheme.
Marchetti A; Barberis M; Papotti M; Rossi G; Franco R; Malatesta S; Buttitta F; Ardizzoni A; Crinò L; Gridelli C; Taddei GL; Clemente C; Scagliotti G; Normanno N; Pinto C
J Thorac Oncol; 2014 Oct; 9(10):1470-6. PubMed ID: 25170637
[TBL] [Abstract][Full Text] [Related]
11. Ceritinib in ALK-rearranged non-small-cell lung cancer.
Shaw AT; Kim DW; Mehra R; Tan DS; Felip E; Chow LQ; Camidge DR; Vansteenkiste J; Sharma S; De Pas T; Riely GJ; Solomon BJ; Wolf J; Thomas M; Schuler M; Liu G; Santoro A; Lau YY; Goldwasser M; Boral AL; Engelman JA
N Engl J Med; 2014 Mar; 370(13):1189-97. PubMed ID: 24670165
[TBL] [Abstract][Full Text] [Related]
12. Concordance of ALK fusion gene-rearrangement between immunohistochemistry and next-generation sequencing.
Wakuda K; Morita M; Sekikawa M; Morikawa N; Miura K; Doshita K; Iida Y; Kodama H; Mamesaya N; Kobayashi H; Ko R; Ono A; Kenmotsu H; Naito T; Murakami H; Muramatsu K; Kawata T; Mori K; Shimizu T; Gon Y; Takahashi T
Int J Clin Oncol; 2024 Feb; 29(2):96-102. PubMed ID: 38183554
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis of NUT Carcinoma Despite False-Negative Next-Generation Sequencing Results: A Case Report and Literature Review.
Wang X; Wang J; Luo X; Lu J; Wang L; Li Q; Wang EH
Onco Targets Ther; 2021; 14():4621-4633. PubMed ID: 34475768
[TBL] [Abstract][Full Text] [Related]
14. CT features and disease spread patterns in ROS1-rearranged lung adenocarcinomas: comparison with those of EGFR-mutant or ALK-rearranged lung adenocarcinomas.
Woo JH; Kim TJ; Kim TS; Han J
Sci Rep; 2020 Oct; 10(1):16251. PubMed ID: 33005033
[TBL] [Abstract][Full Text] [Related]
15. ALK detection in lung cancer: identification of atypical and cryptic ALK rearrangements using an optimal algorithm.
Liu Y; Wu S; Shi X; Liang Z; Zeng X
J Cancer Res Clin Oncol; 2020 May; 146(5):1307-1320. PubMed ID: 32128622
[TBL] [Abstract][Full Text] [Related]
16. Imaging Features and Metastatic Patterns of Advanced
Mendoza DP; Lin JJ; Rooney MM; Chen T; Sequist LV; Shaw AT; Digumarthy SR
AJR Am J Roentgenol; 2020 Apr; 214(4):766-774. PubMed ID: 31887093
[No Abstract] [Full Text] [Related]
17. Isolated 5' Signals Are an Atypical Pattern To Be Considered as Positive for ALK Rearrangement: A Brief Report of Three Cases and Review of the Literature.
Guyard A; Charpy C; Théou-Anton N; Cremades A; Grassin F; Bourgogne A; Leroy K; Pujals A; Copie-Bergman C; Chouaid C; Mansuet-Lupo A
Transl Oncol; 2019 May; 12(5):784-787. PubMed ID: 30909092
[TBL] [Abstract][Full Text] [Related]
18. RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance.
Vollbrecht C; Lenze D; Hummel M; Lehmann A; Moebs M; Frost N; Jurmeister P; Schweizer L; Kellner U; Dietel M; von Laffert M
BMC Cancer; 2018 Nov; 18(1):1158. PubMed ID: 30466405
[TBL] [Abstract][Full Text] [Related]
19. Frequency of ALK Rearrangement by FISH Testing and its Correlation with ALK-IHC in Adenocarcinoma of Primary Lung Origin.
Moatter S; Anwar N; Moatter T; Pervez S
Asian Pac J Cancer Prev; 2018 Jun; 19(6):1735-1738. PubMed ID: 29938474
[TBL] [Abstract][Full Text] [Related]
20. Comparison of ALK status between primary and corresponding lymph node metastatic tumors in lung cancer patients.
Gao Q; Ma H; Wang B; Yao Y; Zhou J; Zhou J
Oncotarget; 2017 Dec; 8(65):108840-108847. PubMed ID: 29312572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
